Thanks ClosetInvestor and LaundryMoney, I appreciate the perspective. I agree if BLA is approved and combo revenue is modestly successful and monotherapy trial has no significant delays it would appear based on simple math we should see a nice return in the next 12-24 months, however, I also assumed the Prostagene acquisition would cause greater SP appreciation and here we are.

This drug is very impressive on HIV and immunotherapy modulation indications alone. Now that it appears we have a strong possibility of non-dilutive financing moving forward, execution on the above items would make one think the SP will significantly appreciate with more general awareness.

TNBC is the big question mark in my mind, which with positive results, could bring the awareness this company needs. If we have interim results by EOY, would be great. I discussed with 2 breast oncologists whether they ever heard of Leronlimab and the answer was no. I talked with two hematologist who also had never heard of the drug or company, one who runs the clinical trials for GVHD at the institution I work at and is involved in CAR T therapies, and she was skeptical. Basically, if academic oncologists running clinical trials at major universities have not heard about this drug, I imagine very few outside of the investment community are aware.
However, if BLA approval occurs this year and TNBC interim results impress the way Dr. Pestell believes they will, this may create the perfect storm we need for the share price to finally maintain an upward trend. Follow this with strong mono-pivotal results and anticipated approval, in conjunction with combo revenue and a positive balance sheet in 2020 and this could get very exciting.

This is just my rationalization of events that my cause increased value in the company. I have no former stock investments/examples to back up this thinking, and therefore more experienced biotech investor’s perspectives are always appreciated.